HOWL Stock Forecast: Werewolf Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Werewolf Therapeutics, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 90 of 100 as at 21 Nov 2026 — among the strongest tenth.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Werewolf Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (85): Sales and profits are climbing, and climbing faster than before.
Revisions (48): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
HOWL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on HOWL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | $10 → $4.00 |
| 18 Nov 2025 | B of A Securities | Maintains | Buy | — |
| 25 Aug 2025 | B of A Securities | Maintains | Buy | — |
| 21 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 9 May 2025 | Wedbush | Maintains | Outperform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Mar 2025 | Wedbush | Reiterates | Outperform | — |
| 14 Jan 2025 | JMP Securities | Maintains | Market Outperform | — |
| 19 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 June 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 4 June 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 3 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 May 2024 | JMP Securities | Reiterates | Market Outperform | — |
| 3 Apr 2024 | JMP Securities | Initiates | Market Outperform | — |
| 7 Mar 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for HOWL.
This page is one stock. Monday covers all of them.
HOWL appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
HOWL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Werewolf Therapeutics, Inc. returned +10.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
HOWL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2.2×
- Price / book
- 6.8×
- EV / EBITDA
- —
Cheaper than 46% of US stocks
Cheaper than 12% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −154.6%
- Return on assets
- −26.1%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Werewolf Therapeutics, Inc. has a market value of $47.9M and an enterprise value of $6.0M.
Revenue in the twelve months to 30 June 2026: $21.0M.
Net income over the same four quarters: −$34.6M, a −164.8% net margin.
Diluted earnings per share, trailing twelve months: −$0.76.
Free cash flow in the twelve months to 30 June 2026: −$30.1M.
Werewolf Therapeutics, Inc. employs 39 people — $538K of revenue per employee.
Data provided by Twelve Data
HOWL and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at HOWL’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Werewolf Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about HOWL
What is the HOWL stock price forecast for 2026-2027?
The median 12-month analyst price target for Werewolf Therapeutics, Inc. is $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is HOWL stock a buy right now?
Of the 1 analyst covering Werewolf Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Werewolf Therapeutics, Inc. 90 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank HOWL?
As at 21 Nov 2026, Werewolf Therapeutics, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).
Will HOWL stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $7, and Ticker Nerd's factor model ranks Werewolf Therapeutics, Inc. 90 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the HOWL stock forecast for 2030?
No analyst covering Werewolf Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HOWL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.
How has HOWL stock performed over the past year?
Werewolf Therapeutics, Inc. returned +10.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Werewolf Therapeutics, Inc. do?
Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions. The company’s current work centers on its proprietary PREDATOR platform, which is used to create INDUKINE and INDUCER molecules intended to activate selectively in diseased tissue while limiting activity in healthy tissue.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics designed to stimulate the immune system for the treatment of cancer and other immune-mediated conditions. The company’s current work centers on its proprietary PREDATOR platform, which is used to create INDUKINE and INDUCER molecules intended to activate selectively in diseased tissue while limiting activity in healthy tissue. Its pipeline includes immune-modulating candidates aimed at solid tumors and specific cancer targets, reflecting a concentration on oncology and immunotherapy. Werewolf Therapeutics Inc. operates as a clinical-stage developer of advanced biologic therapies, with research and development activities spanning tumor-directed immune activation and targeted protein engineering. Headquartered in Watertown, Massachusetts, the company is positioned within the biotechnology sector as a specialist in next-generation cancer therapeutics.
CEO Dr. Daniel J. Hicklin Ph.D. · 39 employees · United States · https://werewolftx.com